Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We continued to execute very well across our international footprint and again took share in Q4 as our global access work and product portfolio strategy have helped broaden our reach in many markets |
| $700 million in organic revenue growth, more than a $1 billion in EBITDA, 600, 000 new customers in our active user base, standing up a plant in Asia without missing a beat, and, of course, launching our G7 product all over the world |
| Total revenue grew by 24% on an organic basis, driven by another year of record customer starts |
| This translates into more than $700 million of organic revenue growth compared to last year as we built strong commercial momentum through recent coverage expansion and the performance of Dexcom's CGM systems |
| Importantly, we delivered this level of growth again while enhancing scale and efficiency of our operations |
| You mentioned before, I think we understand the ramping G7 volumes improving gross, large, and profitability of that product line over time |
| And clearly, we're tracking ahead of our LRP, which I think is both positive signals, I think, for the business in total |
| As a measure of our success for 2023, we not only generated $1 billion in Q4 revenue, we also delivered $1 billion in adjusted EBITDA for the year and generated record levels of free cash flow, which is up nearly 70% compared to 2022 |
| By establishing a disciplined cost culture that focuses years in advance, we are striking the right balance of margin progression while still investing strategically in pathways to support our significant growth opportunities |
| So incredibly bullish on the long-term opportunity there with basal |
| G7 is the most accurate CGM ever launched, and the market's reception to G7 has been exceptional |
| Our product, we have some plans that actually cover non-insulin users for CGM, and we've seen and had wonderful experiences there |
| We know, we have a very good idea where this data comes out because we've seen in all our studies, patients have better outcomes, they're healthier, we end up saving the system money, and those are the outcomes that we're hoping to drive with Stelo over time |
| We'll continue to battle and make sure that that message continues to go out there but as we think about that international book of business, we continue to feel very confident even post-launch of a competitive system we'll do incredibly well there |
| We feel highly confident that when we sit in front of a physician, and we sit in front of an endocrinologist and we sit in front of a parent a child that needs an AID system we feel confident that we are the choice |
| And as you think about this population which really needs and deserves quite frankly the technology to manage their diabetes, we believe that that is a differentiator and a meaningful differentiator going forward |
| And so when you think about the business being historically a pretty significant grower, those pull you down as you start to exclude those things, we are still growing quite well |
| So I'd expect a lot more press releases around where and when we're launching that, but expect that to really take place over the course of the year, which gives us a lot of confidence again in Dexcom ONE being a really incredible growth driver for the long term |
| So we think we're very well positioned, and we'll see where everybody else comes |
| We've got over many years, for example, and AID systems with great outcomes and patients who have done very well there |
| With several trials currently underway, we will continue to add to the growing body of evidence demonstrating Dexcom's unique ability to drive greater health and economic outcomes for all people with diabetes |
| The launch of Stelo also presents a great opportunity to bolster our evidence with a large collection of real world data as we see the impact this product is having on our customers |
| The performance of our sensors has been unparalleled |
| And despite some of the moves and the channel mix changes we've made on the top line; we've been able to maintain a gross margin based on a lot of the work we've done around design to value and a lot of the scale that we've been able to achieve |
| We've done a really nice job to date, creating leverage and opportunities within our operating margin profile |
| Connectivity has always been a distinct advantage for Dexcom and with our recent filing of direct to watch with the FDA and new G7 pump integrations, we are further advancing this leadership position |
| The first is the great operating margins we saw in the fourth quarter |
| As Kevin mentioned earlier, our free cash flow grew by 70% in 2023 as our business continues to scale and become more efficient |
| As it reaches scale, we continue to expect G7's margin profile to improve upon that of our G6 platform |
| Between the ongoing success of G7 and our significantly improved access in recent months, the momentum in our U.S |
| Statement |
|---|
| I think this is the first quarter in a while we've seen international growth below the US growth |
| It's an area that in all candor it's gone and we knew this was going to be a bit of a challenge |
| This year-over-year decline in gross margin was expected as G7 was a much larger percent of our product and customer mix in Q4 compared to a year ago |
| And so that's a negative grower in the quarter |
| That is, believe it or not, it is a challenge in understanding how to identify when those have taken place so that we can get out in front of those folks |
| I think we came in the last year thinking gross margin would be lower in the second half |
| That's not to say that we're not incredibly bullish on the U.S |
| The goal is over the course of the next three to five years to get down into the low 20s |
| So Q1 will be the heaviest burden in terms of as we transition through that |
| Would we expect them to be similar to each other? Does international continue to slow for any reason? And as I think about some of the competitive AID approvals that have happened over in Europe, especially with one year with a competitive CGM |
| So it has been certainly slower than basal |
| I think this year we kind of dropped down to closer to that 26% range |
| It has not been a tremendous driver of our growth |
| So I would expect it to continue to come down every year as we grow into the tax structure that we put in place |
| And so it took a little bit longer |
| And we're not stopping there |
Please consider a small donation if you think this website provides you with relevant information